Upper Gastrointestinal BleedingNCT07114042
HALP as a Novel Score for Prediction of Mortality and re_bleeding in Upper GIT Bleeding
An observational study of Upper Gastrointestinal Bleeding, run by Sohag University at 1 site in Egypt.
Trial summary
Evaluation of the prognostic utility of the HALP score in patients with upper gastrointestinal bleeding, particularly in predicting re_bleeding risk and mortality in internal medicine department in Sohag University Hospitals. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Upper Gastrointestinal Bleeding
- What is being tested?
- Upper endoscopy
- How many people
- 100 participants
- Where
- 1 siteEgypt
- Study dates
- 8 Aug 2025to Feb 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Patients with upper gastrointestinal bleeding
Who may be able to join
- Patients will be included if they were initially admitted to the emergency department, had a confirmed diagnosis of upper gastrointestinal bleeding via endoscopy, and were 18 years of age or older.
Who cannot join
- Incomplete clinical data.
- Lack of laboratory results obtained at emergency department admission necessary for the calculation of HALP score; albumin, hemoglobin (HGB), platelets (PLT), or international normalized ratio (INR).
- Pregnancy
- Patients with missing data on clinical outcomes
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site
Faculty of Medicine -Sohag university
Sohag, 093
Reham R Baeoumy, Master, 0106 3367488, reham.refaat@med.edu.eg
Reham R Baeoumy, Master, 01063367488, reham.refaat@med.edu.eg
About this study
Official title: Moglobin, Albumin, Lymphocyte and Platelet Score as a Novel Predictor of Mortality and Re-bleeding in Patients With Upper Gastrointestinal Bleeding
Evaluation of the prognostic utility of the HALP score in patients with upper gastrointestinal bleeding, particularly in predicting re_bleeding risk and mortality in internal medicine department in Sohag University Hospitals.
Read the detailed description
Study for evaluation of the utility of hemoglobin, Albumin, Lymphocyte and Platelat score in prediction of mortality and re_bleeding in patient with upper gastrointestinal bleeding, Patients will be included if they were initially admitted to the emergency department, had a confirmed diagnosis of upper gastrointestinal bleeding via endoscopy, and were 18 years of age or older.
- Conditions
- Upper Gastrointestinal Bleeding
- Being tested
- Upper endoscopy
- Medical subject headings
- Gastrointestinal Hemorrhage
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Upper endoscopyDiagnostic test
Prediction of upper gastrointestinal r_bleeding and mortality
What is being measured
The primary outcome is the main question the study is designed to answer.
"Mortality"
Measured: 6 months
Incidence of "Re_bleeding"
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Aug 2025
- Study start8 Aug 2025 (estimated)
- Primary completion20 Jan 2026 (estimated)
- Study completionFeb 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Upper Gastrointestinal BleedingStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Reham Refaat Baoumy, Sohag University
- Investigators
- Reham R Baeoumy, Master, Principal investigator, Sohag
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07114042
- Sponsor's protocol ID
- Soh-med--25-7-11MS
- Status last verified
- Aug 2025
- First submitted
- 29 Jul 2025
- Last updated
- 11 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 11 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Moglobin, Albumin, Lymphocyte and Platelet Score as a Novel Predictor of Mortality and Re-bleeding in Patients With Upper Gastrointestinal Bleeding
- ClinicalTrials.gov ID
- NCT07114042
- Acronym / sponsor ID
- Soh-med--25-7-11MS
- Conditions
- Upper Gastrointestinal Bleeding
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 8 Aug 2025 (estimated)
- Primary completion
- 20 Jan 2026 (estimated)
- Study completion
- Feb 2026 (estimated)
- First posted
- 11 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Evaluation of the prognostic utility of the HALP score in patients with upper gastrointestinal bleeding, particularly in predicting re_bleeding risk and mortality in internal medicine department in Sohag University Hospitals.
Detailed description
Study for evaluation of the utility of hemoglobin, Albumin, Lymphocyte and Platelat score in prediction of mortality and re_bleeding in patient with upper gastrointestinal bleeding, Patients will be included if they were initially admitted to the emergency department, had a confirmed diagnosis of upper gastrointestinal bleeding via endoscopy, and were 18 years of age or older.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Patients with upper gastrointestinal bleeding
Key inclusion criteria (1 listed)
- Patients will be included if they were initially admitted to the emergency department, had a confirmed diagnosis of upper gastrointestinal bleeding via endoscopy, and were 18 years of age or older.
Key exclusion criteria (4 listed)
- Incomplete clinical data.
- Lack of laboratory results obtained at emergency department admission necessary for the calculation of HALP score; albumin, hemoglobin (HGB), platelets (PLT), or international normalized ratio (INR).
- Pregnancy
- Patients with missing data on clinical outcomes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Upper endoscopyPrediction of upper gastrointestinal r_bleeding and mortality | Diagnostic test | – |
Primary outcome
"Mortality"
Time frame: 6 months
Incidence of "Re_bleeding"
Time frame: 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Aug 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Upper Gastrointestinal Bleeding
Recruiting
OTSC vs. Angiographic Embolization in Patients With Refractory Non-variceal Upper Gastrointestinal Bleeding
Upper Gastrointestinal Bleeding
Recruiting
Fexuprazan for Prevention of Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy
Acute Coronary Syndromes (ACS), Coronary Artery Disease (CAD)
Not yet recruitingPhase 3
Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic Stroke
Ischemic Stroke, Transient Ischemic Attack
Recruiting
Detection of Blood in the GI Lumen With HemoPill Acute
Upper GI Bleeding
Active, not recruitingObservational study
Impact of Diagnostic and Therapeutic Upper and Lower Gastrointestinal Endoscopic Management on Critically Ill Patients in Fayoum University Hospitals
GIT Bleeding
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Reham R Baeoumy, Master principal investigator
Sohag
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Upper Gastrointestinal Bleeding, run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 11 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Reham R Baeoumy, Master (0106 3367488, reham.refaat@med.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
"Mortality" (time frame: 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Aug 2025.